Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

2.

Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.

Gasche D, Ulle T, Meier B, Greiner RA.

Swiss Med Wkly. 2013 Sep 19;143:w13851. doi: 10.4414/smw.2013.13851.

3.

Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.

Liew D, De Abreu Lourenço R, Adena M, Chim L, Aylward P.

Clin Ther. 2013 Aug;35(8):1110-1117.e9. doi: 10.1016/j.clinthera.2013.06.015. Epub 2013 Jul 26.

PMID:
23891361
4.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
6.

Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.

Cowper PA, Pan W, Anstrom KJ, Kaul P, Wallentin L, Davidson-Ray L, Nikolic E, Janzon M, Levin LÅ, Cannon CP, Harrington RA, Mark DB.

J Am Coll Cardiol. 2015 Feb 10;65(5):465-76. doi: 10.1016/j.jacc.2014.11.034.

7.

Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.

Janzon M, James S, Cannon CP, Storey RF, Mellström C, Nicolau JC, Wallentin L, Henriksson M.

Heart. 2015 Jan;101(2):119-25. doi: 10.1136/heartjnl-2014-305864. Epub 2014 Sep 16.

8.

Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.

Henriksson M, Nikolic E, Ohna A, Wallentin L, Janzon M.

Scand Cardiovasc J. 2014 Jun;48(3):138-47. doi: 10.3109/14017431.2014.902494. Epub 2014 Apr 17.

PMID:
24650118
9.
10.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
11.

Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.

Theidel U, Asseburg C, Giannitsis E, Katus H.

Clin Res Cardiol. 2013 Jun;102(6):447-58. doi: 10.1007/s00392-013-0552-7. Epub 2013 Mar 9. Erratum in: Clin Res Cardiol. 2013 Jun;102(6):477.

12.

Cost-effectiveness of ticagrelor in acute coronary syndromes.

Henriksson M, Janzon M.

Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):9-18. doi: 10.1586/erp.12.89. Review.

PMID:
23402441
13.

Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.

Mejía A, Senior JM, Ceballos M, Atehortúa S, Toro JM, Saldarriaga C, Mejía ME, Ramírez C.

Biomedica. 2015 Oct-Dec;35(4):531-40. doi: 10.7705/biomedica.v35i4.2620.

14.

[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].

Molina-Cuadrado E, Mateo-Carrasco H, Nieto-Guindo P, Rodríguez-Gómez P.

Farm Hosp. 2014 Jul 1;38(4):266-75. doi: 10.7399/fh.2014.38.4.1132. Spanish.

15.

CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.

Jiang M, You JH.

Cardiovasc Drugs Ther. 2017 Feb;31(1):39-49. doi: 10.1007/s10557-016-6705-y.

PMID:
27924429
16.

Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2006;24(7):709-26. Review.

PMID:
16802846
17.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

PMID:
19332184
18.

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.

Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA.

Ann Intern Med. 2014 Feb 18;160(4):221-32.

PMID:
24727840
19.

Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Sep 1;10(5):331-42. doi: 10.2165/11633970-000000000-00000.

PMID:
22853743
20.

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N, McEntee J, Dundar Y, Richardson M, Fisher M.

Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290. Review.

Supplemental Content

Support Center